Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
Author:
Publisher
Baishideng Publishing Group Inc.
Subject
Oncology
Reference20 articles.
1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
2. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
3. Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer
4. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
5. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States;Future Oncology;2024-07-29
2. Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI);International Journal of Clinical Oncology;2024-06-10
3. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective;Urologic Oncology: Seminars and Original Investigations;2024-06
4. Novel treatment strategies to overcome resistance in prostate cancer;Therapy Resistance in Prostate Cancer;2024
5. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2022-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3